Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 15, 2021. The filing details the final voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes
No material financial changes are reported in this document. The primary events are the election of Class III directors and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of shareholder voting results.
Important Facts for Investors
- Director Elections: Santo J. Costa, Julie Krop, M.D., and Marco Taglietti, M.D. were elected as Class III directors for a three-year term.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent auditor for fiscal year 2021.
- Voting Participation: Significant broker non-votes (9,566,915) were recorded for the director elections, while the auditor ratification received 25,081,651 votes for and 344,559 votes against.
- Emerging Growth Status: The company is identified as an emerging growth company.